![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Patient characteristics and utilization of protease inhibitors in hepatitis C virus (HCV) patients in a large payer database
|
|
|
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
Neeta Tandon1, Candace Gunnarsson2, Avinash Prabhakar3
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2S2 Statistical Solutions, Inc., Cincinnati, OH, USA; 3Janssen Services, LLC, Titusville, NJ, USA
![EASL1.gif](../images/050713/050613-8/EASL1.gif)
![EASL2.gif](../images/050713/050613-8/EASL2.gif)
![EASL3.gif](../images/050713/050613-8/EASL3.gif)
![EASL4.gif](../images/050713/050613-8/EASL4.gif)
![EASL5.gif](../images/050713/050613-8/EASL5.gif)
![EASL6.gif](../images/050713/050613-8/EASL6.gif)
![EASL7.gif](../images/050713/050613-8/EASL7.gif)
![EASL8.gif](../images/050713/050613-8/EASL8.gif)
![EASL9.gif](../images/050713/050613-8/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|